ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of “Moderate Buy” by Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.1429.

A number of analysts have issued reports on the stock. Chardan Capital reiterated a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th.

ProQR Therapeutics Stock Up 5.2%

Shares of NASDAQ:PRQR opened at $2.21 on Monday. The firm has a fifty day moving average of $2.37 and a two-hundred day moving average of $2.23. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $3.10. The firm has a market capitalization of $232.51 million, a P/E ratio of -4.70 and a beta of 0.17.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. The firm had revenue of $3.38 million for the quarter, compared to analyst estimates of $7.05 million. Equities research analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in PRQR. Affinity Asset Advisors LLC lifted its holdings in ProQR Therapeutics by 16.3% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after purchasing an additional 459,512 shares during the last quarter. Aberdeen Group plc raised its position in shares of ProQR Therapeutics by 24.2% in the third quarter. Aberdeen Group plc now owns 2,298,823 shares of the biopharmaceutical company’s stock valued at $4,896,000 after purchasing an additional 448,475 shares during the period. Citadel Advisors LLC lifted its stake in shares of ProQR Therapeutics by 73.2% in the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 277,749 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of ProQR Therapeutics by 86.3% during the 3rd quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock worth $889,000 after buying an additional 193,260 shares during the period. Finally, Palo Alto Investors LP acquired a new position in ProQR Therapeutics in the 3rd quarter valued at $402,000. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.